Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer
Background Ovarian cancer is the most lethal gynecological malignancy, with limited treatment options after failure of standard therapies. Despite the potential of poly(ADP-ribose) polymerase inhibitors in treating DNA damage response (DDR)-deficient ovarian cancer, the development of resistance and...
Saved in:
| Main Authors: | Lorna Rodriguez-Rodriguez, Rui Huang, Mihaela Cristea, Qianqian Zhao, Adrian Kohut, Hua Yu, Mihae Song, Antons Martincuks, Chunyan Zhang, Edward W Wang, Theresa Austria, Yi-Jia Li, Nicole Lugo Santiago, Rosemarie Martinez Borrero, Binghui Shen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-04-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/4/e007716.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies
by: Shant Apelian, et al.
Published: (2025-05-01) -
Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization
by: Chen Xuan, et al.
Published: (2025-07-01) -
Discovery of 2‑Pyrazolines That Inhibit the Phosphorylation of STAT3 as Nanomolar Cytotoxic Agents
by: Tejaswini P. Siddappa, et al.
Published: (2025-01-01) -
Tyrosine phosphorylation of both STAT5A and STAT5B is necessary for maximal IL-2 signaling and T cell proliferation
by: Jian-Xin Lin, et al.
Published: (2024-08-01) -
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
by: Changli Qian, et al.
Published: (2023-01-01)